MediumEndocrinologyType 2 diabetes with cardiovascular diseaseau-amcau-racp
A 63-year-old man with type 2 diabetes for 10 years, prior myocardial infarction and eGFR 65 mL/min/1.73 m² is on maximal tolerated metformin but has an HbA1c of 8.2% (66 mmol/mol). According to the 2024 Australian type 2 diabetes glycaemic management algorithm, which additional agent is preferred to reduce both cardiovascular risk and improve glycaemic control?